A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma. Issue 1 (29th August 2019)

• Record Type: Journal Article
• Authors: Zhang, Yiyin; Xu, Jin; Hua, Jie; Liu, Jiang; Liang, Chen; Meng, Qingcai; Wei, Miaoyan; Zhang, Bo; Yu, Xianjun; Shi, Si
• Is Part Of: Journal for immunotherapy of cancer. Volume 7:Issue 1(2019)
• Publication Date: 2019-08-29
• Subjects: Pancreatic ductal adenocarcinoma -- PD-L2 -- Immune marker -- Prognosis -- TGF-β2; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/s40425-019-0703-0
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Programmed cell death protein 1 (PD-1) is a key immune checkpoint that regulates peripheral tolerance and protects against autoimmunity. Programmed death ligand-2 (PD-L2) is a less studied ligand to PD-1 and has yet to be fully explored, especially in pancreatic ductal adenocarcinoma (PDAC). Methods: In this study, we performed immunohistochemistry to detect the PD-L2, CD3, CD8, transforming growth factor-β2 (TGF-β2) and FOXP3 levels in paraffin sections from 305 patients with resected PDAC as a training set. Expression levels of intratumoral and stromal immune markers were compared in relation to survival using Kaplan-Meier curves, random survival forest model and survival tree analysis. A multivariable Cox proportional-hazards model of associated markers was used to calculate the risk scores. Results: PD-L2 was expressed in 71.5% of PDAC samples and showed strong correlations with CD3+, CD8+ T cells and FOXP3+ regulatory T cell densities. High levels of intratumoral PD-L2 and FOXP3 were related to poor survival; only stromal FOXP3 overexpression was associated with worse prognosis. Four patterns generated from survival tree analysis demonstrated that PD-L2 low stromal FOXP3 low patients had the longest survival, while PD-L2 high intratumoral CD3 low patients had the shortest survival ( P < 0.001). The area under the curve was 0.631(95% confidence interval (CI): 0.447–0.826) for the immune marker-based signature and 0.549 (95% CI: 0.323–0.829; P < 0.001) for the clinical parameter-based signature, which was consistent with the results in the validation set including 150 patients ( P < 0.001). A higher risk score indicated shorter survival and could serve as an independent prognostic factor. PD-L2 was also showed associated with TGF-β2 and other immune molecules based on bioinformatics analysis. Conclusions: Our work highlighted PD-L2 as a promising immunotherapeutic target with prognostic value combined with complex tumor infiltrating cells in PDAC.